Tuesday,  January 1, 2013 • Vol. 13--No. 166 • 34 of 37 •  Other Editions

(Continued from page 33)

• Roughly one-third of the world's population is estimated to be infected with the bacteria causing tuberculosis. The disease is rare in the U.S., but kills about 1.4 million people a year worldwide. Of those, about 150,000 succumb to the increasingly common drug-resistant forms of the disease. About 60 percent of all cases are concentrated in China, India, Russia and Eastern Europe.
• Sirturo, known chemically as bedaquiline, is the first medicine specifically designed for treating multidrug-resistant tuberculosis. That's a form of the disease that cannot be treated with at least two of the four primary antibiotics used for tuberculosis.
• The standard drugs used to fight the disease were developed in the 1950s and 1960s.
• ___

Survivors of Oregon bus crash that killed 9 say some passengers were ejected through windows

• PENDLETON, Ore. (AP) -- Survivors of a bus crash that killed nine people on a partly icy section of interstate in rural Eastern Oregon said Monday some passengers were thrown from the vehicle through broken windows after it skidded out of control, smashed through a guardrail and plummeted 200 feet down an embankment.
• When the tour bus came to a rest, terrified passengers looked around for their loved ones.
• "Some mothers screamed to find their son or daughter," said Jaemin Seo, a 23-year-old exchange student from Suwon, South Korea.
• The charter bus, owned by a British Columbia company, crashed Sunday just east of Pendleton while returning to Canada from Las Vegas -- one of the stops on a nine-day western tour.
• Aboard were 48 people, some of them exchange students from South Korea. Some passengers were from British Columbia, and some from Washington state. Investigators say there also may have been a Japanese passenger and one from Taiwan, and they're working with consular officials from those nations to identify them.
• ___



(Continued on page 35)

© 2012 Groton Daily Independent • To send correspondence, click here.